David Lee Johnson - Feb 18, 2025 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
Chief Operating Officer
Signature
/s/ Joseph R. Young, Attorney-in-Fact
Stock symbol
VERA
Transactions as of
Feb 18, 2025
Transactions value $
$0
Form type
4
Date filed
2/20/2025, 04:05 PM
Previous filing
Jul 3, 2024
Next filing
Feb 21, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Award $0 +26.9K $0.00 26.9K Feb 18, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERA Stock Option (right to buy) Award $0 +53.8K $0.00 53.8K Feb 18, 2025 Class A Common Stock 53.8K $29.18 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service through each vesting date.
F2 1/48 of the shares subject to the stock option will vest and become exercisable on March 18, 2025, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.